Tirzepatide in Netherlands: Mounjaro access

In the Netherlands, tirzepatide is authorised and sold under the brand name Mounjaro by Eli Lilly Nederland B.V., headquartered in Utrecht. The European Commission granted the marketing authorisation on 15 September 2022^[1], covering two indications: type-2 diabetes in adults and, separately, weight management in adults with obesity or overweight plus a weight-related comorbidity. Both indications are active in the Netherlands today, but the path to reimbursed access differs sharply between them.

The marketing authorisation: what it covers

Mounjaro holds a centrally authorised EMA licence, which means it is valid across all EU and EEA member states without a separate Netherlands-specific application. The marketing authorisation holder is Eli Lilly Nederland B.V., and the ATC code is A10BX16^[1]. The type-2 diabetes indication covers adults whose blood sugar is insufficiently controlled on existing therapy, as monotherapy when metformin is unsuitable or as an add-on to other diabetes medicines. The weight-management indication covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as hypertension, dyslipidaemia, obstructive sleep apnea, or cardiovascular disease.

The SmPC was last updated in February 2026, reflecting ongoing post-authorisation pharmacovigilance. In December 2024 the EMA assessed tirzepatide for obstructive sleep apnea, and in January 2026 it assessed the drug for heart failure with preserved ejection fraction in adults with obesity. In June 2026 the EMA published an outcome on cardiovascular risk reduction. None of these have yet produced a formal label extension in the Netherlands, and the current authorised indications in the Netherlands remain type-2 diabetes and weight management.

December 2025: the paediatric extension opinion

On 12 December 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending that Mounjaro be extended to children and adolescents aged 10 and over with type-2 diabetes not satisfactorily controlled with diet and physical activity^[2]. The European Commission typically ratifies CHMP opinions within two months. Once ratified, the paediatric type-2 diabetes indication becomes part of the centralised authorisation and applies in the Netherlands automatically. Reimbursement under Dutch health insurance is a separate step and does not follow automatically.

Prescription status in the Netherlands

Mounjaro is prescription-only (UR) in the Netherlands, consistent with the EMA authorisation. A Dutch general practitioner or specialist can prescribe it within the authorised indications. The drug is not available over the counter, and online pharmacies operating without a valid Dutch pharmacy licence cannot legally dispense it. The prescribing information (SmPC) specifies the standard contraindications that apply across the EU: personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, and prior serious hypersensitivity to tirzepatide. SURPASS-2, the head-to-head Phase 3 trial against semaglutide in type-2 diabetes, reported that tirzepatide at 15 mg reduced HbA1c by 2.30 percentage points versus 1.86 on semaglutide^[3], which was part of the evidence base the EMA reviewed before authorisation.

Reimbursement: the Dutch GVS and what it means for patients

The Netherlands uses the Geneesmiddelenvergoedingssysteem (GVS) to determine which prescription medicines are covered by the basic health insurance package (basispakket). Zorginstituut Nederland, the national health care institute, advises the Minister of Health on which drugs meet the package criteria of effectiveness, necessity, cost-effectiveness, and feasibility. A positive EMA authorisation does not automatically translate into GVS reimbursement. The Minister of Health decides on inclusion, and restrictions or conditions often apply.

For the type-2 diabetes indication, tirzepatide (Mounjaro) has been included in the GVS with prescribing conditions that align with the EMA indication. For the weight-management indication, the reimbursement picture in the Netherlands has been more restricted. As of July 2026, tirzepatide for weight management is not broadly reimbursed through the basispakket in the same manner as semaglutide for obesity: Dutch health policy has applied a tiered, condition-based approach to anti-obesity medicines under which GLP-1 class drugs require a referral to a specialist weight-management programme. Patients and prescribers should verify the current GVS status directly with their health insurer or through the official Dutch GVS register, as the reimbursement conditions for this drug class are subject to revision. See the Netherlands regulation hub for the most current status.

Grey-market tirzepatide and what the rules say

Because Mounjaro is prescription-only and reimbursement for the obesity indication is restricted, some Dutch residents seek tirzepatide through online vendors selling "research-grade" or "compounded" versions. The Netherlands Inspectorate for Health and Youth Care (IGJ) treats unlicensed medicines as illegal if they are sold or dispensed without the appropriate authorisation. Tirzepatide purchased outside the regulated pharmacy chain is not subject to the quality and purity standards that apply to the branded product, and the IGJ has enforcement authority over pharmacies and internet sales. The EMA-authorised Mounjaro pens are the only legally compliant route.

What the evidence shows for the indications licensed in the Netherlands

The SURMOUNT-1 trial, which underpinned the weight-management authorisation, enrolled 2,539 adults with obesity but without type-2 diabetes and reported a mean body-weight reduction of 20.9% at 72 weeks on tirzepatide 15 mg weekly versus 3.1% on placebo^[4]. Between 50 and 57% of participants on the higher doses reached at least 20% weight loss. The adverse-event profile was dominated by gastrointestinal events, dose-dependent and largely mitigated by slow titration. These results formed part of the EMA assessment; the Netherlands-approved label reflects this population and dose range.

What we do not yet know

Several questions remain open for Dutch patients and prescribers. First, the reimbursement conditions for the weight-management indication are subject to ongoing policy review: the Dutch government has signalled interest in expanding access to anti-obesity medicines but has also imposed conditions around specialist referral and programme participation that may change. Second, the paediatric type-2 diabetes extension, expected to be ratified by the European Commission in early 2026, will bring new prescribing questions around Dutch paediatric specialist access and whether the GVS will extend coverage to that group. Third, the long-term question common to all GLP-1 class drugs applies here: SURMOUNT-4 showed that stopping tirzepatide leads to substantial weight regain, which raises durability and chronic-use questions that Dutch formulary decisions will eventually have to address.

Fourth, the post-authorisation assessments that the EMA has published since 2024 (on obstructive sleep apnea, heart failure with preserved ejection fraction, and cardiovascular risk reduction) may eventually produce label expansions. Each of those would require a fresh Dutch reimbursement assessment by Zorginstituut Nederland before Dutch health insurers would cover the new indication. For detail on the underlying clinical evidence, see the tirzepatide drug page and the trial summaries linked there.

Where this lands

Tirzepatide is a fully authorised, prescription-only medicine in the Netherlands for type-2 diabetes and weight management in the adult population. The EMA licence is valid and current; the marketing authorisation holder is based in Utrecht. Reimbursement through the basispakket depends on the indication and the conditions Zorginstituut Nederland and the Minister of Health have set, and those conditions differ between the diabetes and obesity routes. For a cross-country comparison, see tirzepatide regulation by country. If you are considering tirzepatide, the right starting point is a conversation with a Dutch GP or internist who can assess eligibility under the current prescribing and reimbursement criteria.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Tirzepatide is a prescription-only medicine in the Netherlands. Always consult a qualified healthcare professional before using any prescription medicine. PeptideMethods.com does not sell, distribute, or facilitate the sale of any medicine or peptide product.

Regulatory disclaimer: This page reflects our understanding of the regulatory status as of July 2026. Regulations change. Verify with the official regulator before making any decision. PeptideMethods.com is not a law firm and does not provide legal advice.